SEARCH

SEARCH BY CITATION

Conflict of interest statements from APASL Hepatitis C working party members

  1. Conflict of interest statements from APASL Hepatitis C working party members
  2. References

G McCaughan

• Research grant support—Roche

• Advisory board—Roche, Schering Plough (SP)

M Omata

• Advisory board—Roche, Bristol Myers Squibb

G Dore

• Research grant support—Roche and SP

• Advisory board—Roche and SP

• Travel grants—Roche and SP

E Gane

• Advisory board—Glaxo Smith Kline (GSK), Novartis

R Guan

• Advisory board—GSK, SP, SciGen, SciClone Pharmacueticals

T Piratvisuth

• Advisory Board—Roche, SP, GSK and Novartis

J Sollano

• Research grant support—GSK, Bristol Myers Squibb, Gilead, Eisai, Otsuka

• Advisory board—GSK, SP, Eisai, Novartis

References

  1. Conflict of interest statements from APASL Hepatitis C working party members
  2. References
  • 1
    Ferreira-Gonzalez A, Shiffman ML. Use of diagnostic testing for managing hepatitis C virus infection. Semin. Liver Dis. 2004; 24 (Suppl. 2): 918.
  • 2
    Forns X, Costa J. HCV virological assessment. J. Hepatol. 2006; 44: S359.
  • 3
    Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C viral genotypes. Hepatology 2005; 42: 96273.
  • 4
    Chevaliez S, Pawlotsky J-M. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin. Liver Dis. 2005; 9: 37182.
  • 5
    Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol. 2006; 1: 10312.
  • 6
    Saldanha J, Lelie N, Heath A, WHO Collaborative Study Group. Establishment of the first International Standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang. 1999; 76: 14958.
  • 7
    Laperche S, Elghouzzi MH, Morel P et al. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 2005; 45: 196572.
  • 8
    Alter MJ, Kuhnert WL, Finelli L; Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 2003; 52: 113.
  • 9
    National Institutes of Health. Consensus Development Conference Statement. Management of hepatitis C. Hepatology 2002; 36 (Suppl. 1): S1252.
  • 10
    World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 1999; 6: 3547.
  • 11
    Kaldor JM, Dore GJ, Correll PKL. Public health challenges in hepatitis C virus infection. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E8390.
  • 12
    Kao J-H, Chen D-S. Transmission of hepatitis C virus in Asia: past and present perspectives. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E916.
  • 13
    Tanaka E, Kiyosawa K. Natural history of acute hepatitis C. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E97104.
  • 14
    Amarapurkar D. Natural history of hepatitis C virus infection. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E10510.
  • 15
    Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36: S10613.
  • 16
    European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis. 2005; 41: 4551.
  • 17
    Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): S3546.
  • 18
    Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 2006; 13: 3441.
  • 19
    McCaughan GW, McGuiness PH, Bishop GA et al. Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors. Med. J. Aust. 1992; 157: 2313.
  • 20
    Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome Semin. Liver Dis. 2000; 20: 1735.
  • 21
    Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001; 194: 1395406.
  • 22
    Farci P, Alter HJ, Wong D et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N. Engl. J. Med. 1991; 352: 98104.
  • 23
    Farci P, Alter HJ, Shimoda A et al. Hepatitis C virus associated fulminant hepatic failure. N. Engl. J. Med. 1996; 335: 6314.
  • 24
    Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin. Liver Dis. 2005; 25: 717.
  • 25
    Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 2006; 3: 4752.
  • 26
    Feld JJ, Lian TJ. Hepatitis C—identifying patients with progressive liver injury. Hepatology 2006; 43: S194206.
  • 27
    Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels. J. Hepatol. 2005; 42: 26674.
  • 28
    Yano M, Kumada H, Kage M et al. The long term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 133440.
  • 29
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrect J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 2001; 14: 7647.
  • 30
    Alberti A. What is mild chronic hepatitis C? Hepatol. Rev. 2005; 2: 1923.
  • 31
    Serfaty L, Aumaitre H, Chazouilleres O et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 143540.
  • 32
    Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur. J. Gastroenterol. Hepatol. 1996; 8: 3248.
  • 33
    Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference: management of hepatitis C: 2002. Hepatology 2002; 36 (Suppl. 1): S12.
  • 34
    Strader DB, Wright T, Thomas DL, Seef LB. Diagnosis management and treatment of hepatitis C. Hepatology 2004; 39: 114871.
  • 35
    Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000; 132: 51724.
  • 36
    Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 130313.
  • 37
    Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E13440.
  • 38
    Yoshida H, Shiratori Y, Moriyarna M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program in Japan of cirrhotic and non-cirrhotic patients with chronic hepatitis C. Ann. Intern. Med. 1999; 131: 17481.
  • 39
    Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL, the International Hepatitis Interventional Therapy Group. Health-related quality of life in chronic hepatitis C. Impact of disease and treatment response. Hepatology 1999; 30: 5505.
  • 40
    Farrell GC. Consensus among consensus conferences on management of hepatitis C: what we knew then and are still sure about, what we are newly sure about and what we still need to know. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E1269.
  • 41
    Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 2002; 97: 261418.
    Direct Link:
  • 42
    Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): S5764.
  • 43
    Afdhal N. The natural history of hepatitis C. Semin. Liver Dis. 2004; 24 (Suppl. 2): 38.
  • 44
    Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment induced viral clearance. Gastroenterology 2003; 125: 808.
  • 45
    Lechmann M, Meyer MF, Monazahian M et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J. Med. Virol. 2004; 73: 38791.
  • 46
    Nomura H, Sou S, Tanimoto H et al. Short term interferon a therapy for acute hepatitis C: a randomised controlled trial. Hepatology 2004; 39: 121319.
  • 47
    Jaeckel E, Cornberg M, Wedemeyer MD et al. Treatment of acute hepatitis C with interferon-α 2b. New Engl. J. Med. 2001; 345: 14527.
  • 48
    Delwaide J, Bourgeois N, Gerard C et al. Treatment of interferon with interferon-α2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment. Pharmacol. Ther. 2004; 20: 1522.
  • 49
    Santantonio T, Fasano M, Sinisi E et al. Efficacy of a 24-week course of peg-interferon α2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol. 2005; 42: 32933.
  • 50
    Kamal SM, Fouly AE, Kamel RR et al. Peginterferon α2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 6328.
  • 51
    Kamal SM, Madwar MA, Ismail A et al. Peginterferon alpha compared to conventional interferon alpha plus ribavirin combination therapy in symptomatic acute hepatitis C: a randomized trial of treatment onset, duration and cost effectiveness. Hepatology. 2004; 37 (Suppl.): 178A (Abstract 37).
  • 52
    Roca P, Bailly F, Chevallier M et al. Early treatment of acute hepatitis C with interferon α2b or interferon α2b plus ribavirin: study of 16 patients. Gastroenterol. Clin. Biol. 2003; 27: 2949.
  • 53
    Kamal SM, Ismail A, Graham CS et al. Pegylated interferon α therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39: 172131.
  • 54
    Kamal SM, Moustefa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43: 92331.
  • 55
    Vedemeyer H, Jackel E, Wiegand J et al. Whom, when, how? Another piece of evidence for early treatment of acute hepatitis C. Hepatology 2004; 39: 12013.
  • 56
    Poynard T, McHutchison J, Goodman Z, Ling M-H, Albrecht J. Is an ‘a la carte’ combination interferon alfa2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31: 21118.
  • 57
    Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E14151.
  • 58
    Zeuzem S, Diago M, Gane E et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2005; 128: 15312.
  • 59
    Darling JM, Fried MW. Optimizing treatment regimens in hepatitis C. Clin. Liver Dis. 2006; 10: 83550.
  • 60
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 61
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 97582.
  • 62
    Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 34655.
  • 63
    Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 2006; 44: 97103.
  • 64
    Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 2004; 40: 9939.
  • 65
    Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks HCV genotype 2 or 3. N. Engl. J. Med. 2005; 352: 260917.
  • 66
    Dalgard O, Bjøro K, Hellum KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 12605.
  • 67
    Chutaputti A. Adverse effects and other safety aspects of hepatitis C antivirals. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E15663.
  • 68
    Chow WC. Hepatitis C: retreatment and treatment of patients with renal failure. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E1525.
  • 69
    Jacobsen IM, Ahmed F, Russo MW et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results [Abstract]. Gastroenterology 2003; 124: A540.
  • 70
    Shiffmann ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004; 126: 101523.
  • 71
    Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 14939.
  • 72
    Nishiguchi S, Kuroki T, Nakatami S. Randomised trial of effects of interferon on the incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 10515.
  • 73
    Sarin SK. What should we advise about adjunctive therapies, including herbal medicines for chronic hepatitis C? J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E16471.
  • 74
    Sherman KE, Sjogren M, Creager RL et al. Combination therapy with thymosin alphal and interferon for the treatment of chronic hepatitis C infection; a randomized, placebo controlled double-blind trial. Hepatology 1998; 27: 112835.
  • 75
    Armstrong G, Alter M, McQuillan G, Margollis H. The past incidence of HCV: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 77782.
  • 76
    Kim W, Brown R, Terrault N, El-Serag H. Burden of liver disease in the United States. Hepatology 2002; 36: 22742.
  • 77
    El Serag H, Mason A. Risk factors for rising rates of primary liver cancer in the United States. Arch. Intern. Med. 2000;160: 322730.
  • 78
    Kim W. The burden of hepatitis C in the Unites States. Hepatology 2002; 36 (Suppl. 1): S304.
  • 79
    Australian and New Zealand Liver Transplant Registry (ANZLTR). ANZLTR 16th Annual Report. Brisbane: ANZLTR, 2004. Available from URL: http://www.anzltr.org
  • 80
    Propst A, Propst T, Zangerl G, Ofner D, Judmaier G, Vogel W. Prognosis and life expectancy in chronic liver disease. Dig. Dis. Sci. 1995; 40: 180515.
  • 81
    Gines P, Qunitero E, Arroyo V. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 1228.
  • 82
    Lucey M, Brown K, Everson G et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl. Surg. 1997; 3: 62837.
  • 83
    Devlin J, O'Grady J. Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut 1999; 45 (Suppl. 6): VI1–22.
  • 84
    Carithers R. AASLD listing criteria for liver transplantation. Liver Transpl. 2000; 6: 122135.
  • 85
    Consensus Conference. Indications for liver transplantation: text of recommendations (long version). Liver Transpl. 2006; 12: 9981011.
  • 86
    Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 6939.
  • 87
    McPeake JR, O'Grady JG, Portmann B et al. Liver transplantation for primary hepatocellular carcinoma: tumour size and number determine outcome. J. Hepatol. 1993; 18: 22634.
  • 88
    Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann. Surg. 1993; 218: 14551.
  • 89
    Haug CE, Jenkins RL, Rohrer RJ et al. Liver transplantation for primary hepatic cancer. Transplantation 1992; 53: 3763.
  • 90
    Porayko M, Wiesner R. Management of ascites in patients with cirrhosis: what to do when diuretics fail. Postgrad. Med. 1992; 92: 15566.
  • 91
    Riordan SM, Williams R. Treatment of hepatic encephalopathy. N. Eng J. Med. 1997; 337: 4739.
  • 92
    Andreu M, Sola R, Sitges-Serra A. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104: 11338.
  • 93
    Kim W, Tyherneau T, Evans R, Steers J, Wiesner R, Dickson E. Can resource utilisation and quality of life post-transplant be predicted by perioperative variables? Hepatology 1996; 24:301A.
  • 94
    Selberg O, Bottcher J, Tusch G, Pichlmayr R, Henkel E, Muller M. Identification of high and low risk patients before liver transplantation: a prospective cohort study of nutritional and ametabolic parameters in 150 patients. Hepatology 1997; 25: 6527.
  • 95
    Krowka M, Cortese D. Hepatopulmonary syndrome: current concepts in diagnostic and therapeutic considerations. Chest 1994; 105: 152837.
  • 96
    Brown J, Lake J, Ascher N, Emond J, Roberts J. Predictors of cost of liver transplantation. Hepatology 1996; 24: 299A.
  • 97
    Gines A, Escorsell A, Gines P. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 22936.
  • 98
    Brown R, Lombardero M, Lake J. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996; 62: 178892.
  • 99
    Yao F, Xiao L, Bass N et al. Liver transplantation for hepatocellular carcinoma: a 5-year prospective study validating expanded criteria applied to preoperative imaging. Hepatology 2006;44: 191A.
  • 100
    Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C kinetics during and immediately after transplantation. Hepatology 2002; 35: 6807.
  • 101
    Duvoux C, Pawlotsky JM, Cherqui D et al. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. Transplantation 1995; 60: 45761.
  • 102
    DiMartino V, Saurini F, Samuel D et al. Longitudinal study of intra-hepatic HCV replication after liver transplantation. Hepatology 1997; 26: 134350.
  • 103
    Ballardini G, De Raffele E, Groff P et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted HCV-infected liver. Liver Transpl. 2002; 8: 1020.
  • 104
    Gane E, Naoumov N, Qian K et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 16777.
  • 105
    Fukumoto T, Berg T, Ku Y et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24: 13514.
  • 106
    Lim H, Lau G, Davis G, Dolson D. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted HCV infection. Gastroenterology 1994; 106: 24851.
  • 107
    Gane E, Portmann B, Naoumov N et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 1996; 334: 8217.
  • 108
    Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 20210.
  • 109
    Feray C, Caccamo L, Alexander G, EUROHEP Group. HCV and liver transplantation: preliminary results of a European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117: 61925.
  • 110
    Forman L, Lewis J, Lewis J et al. Association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 88996.
  • 111
    Sanchez-Fueyo A, Restrepo J, Qunito L et al. Impact of recurrence of HCV infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 563.
  • 112
    Berenguer M, Prieto M, Rayon J et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 8528.
  • 113
    Pruthi J, Medkiff K, Esrason K et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001; 7: 81115.
  • 114
    Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol. 2000; 32: 67384.
  • 115
    Fasola C, Netto G, Onaca N et al. A more severe HCV recurrence post-liver transplant observed in recent years may be explained by use of lower dose corticosteroid maintenance protocols. Hepatology 2003; 38: 226A.
  • 116
    Burak K, Kremers Q, Batts K et al. Impact of CMV, year of transplant and donor age on outcomes after liver transplantation. Liver Transpl. 2003; 8: 3629.
  • 117
    Brillanti S, Vivarelli M, De Ruvo N et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl. 2002; 8: 8848.
  • 118
    Shiffman M, Stravitz R, Contos M et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl. 2004; 10: 124855.
  • 119
    Wiesner R, Demetris A, Seaberg E et al. Acute hepatic allograft rejection: risk factors and impact on outcome. Hepatology 1998; 28: 63845.
  • 120
    Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 82330.
  • 121
    Rosen H, Shackleton C, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am. J. Gastroenterol. 1997; 92: 14537.
  • 122
    Sheiner P, Schwartz M, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 304.
  • 123
    Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. Surgery 1996; 19: 4526.
  • 124
    Berenguer M, Prieto M, Cordoba J et al. Early development of chronic hepatitis in recurrent hepatitis C infection after liver transplantation—association with rejection. J. Hepatol. 1998; 28: 75663.
  • 125
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence hepatitis C: results of the NIDDK Liver Transplant database. Liver Transpl. 1999; 5: S10714.
  • 126
    Gaglio P, Park J, Lefkowitch J, Emond J, Brown R. Treatment of acute cellular rejection is associated with severe HCV recurrence in living and deceased donor liver transplant recipients. Hepatology 2003; 38: 651A.
  • 127
    Berenguer M, Crippin J, Gish R et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 3441.
  • 128
    Fasola C, Heffron T, Sher R et al. Multicentre randomised HCV-3 post-liver transplantation—2 year interim report. Hepatology 2006; 44: 403A.
  • 129
    Zervos XA, Weppler D, Fragulidis GP et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998; 65: 10446.
  • 130
    Levy G, Grazi G, Sanjuan F et al. 12-month follow-up analysis of a multicentre, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006; 10: 146472.
  • 131
    Rosen HR, Hinrichs DJ, Gretch DR et al. Association of multispecific CD4 response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999;117: 92632.
  • 132
    Terrault N, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006; 12: 1192204.
  • 133
    Barcena R, Gil-Grande L, Moreno J et al. Partial splenic embolisation for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin. Transplantation 2005; 79:16345.
  • 134
    Durlik M, Gaciong Z, Roewinska D et al. Long-term results of treatment of chronic hepatitis B and C with interferon in renal allograft recipients. Transplant Int. 1998; 11: S1359.
  • 135
    Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients. Transplantation 1995; 59: 142631.
  • 136
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 51216.
  • 137
    Kramer P, Ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 98990.
  • 138
    Feray C, Samuel D, Gigou M, Paradis V, Reynes M, Bismuth H. An open trial of interferon-a recombinant for hepatitis C after liver transplantation. Hepatology 1995; 22: 10849.
  • 139
    Stravitz RT, Shiffman ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl. 2004; 10: 8508.
  • 140
    Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 28998.
  • 141
    Oton E, Barcena R, Garcia-Garzon S et al. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. Transplant. Proc. 2005; 37: 39634.
  • 142
    Castells L, Vargas V, Allende H et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J. Hepatol. 2005; 43: 539.
  • 143
    Shergill AK, Khalili M, Straley S et al. Applicability, tolerability and efficacy of pre-emptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am. J. Transplant. 2005; 5: 11824.
  • 144
    Calmus Y, Samuel D, Messner M et al. Multicenter randomized trial in HCV-infection patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: 18-month report. Hepatology 2006; 44: 189A.
  • 145
    Kuo A, Lan B, Feng S et al. Long-term histologic effects of pre-emptive therapy in liver transplant recipients with HCV infection. Hepatology 2006; 44: 189A.
  • 146
    Crippin J, McCashland T, Terrault N et al. Pilot study of tolerability and efficacy of antiviral therapy for HCV-infected patients awaiting liver transplantation. Liver Transpl. 2002; 8: 3505.
  • 147
    Everson G, Trotter J, Forman L et al. Treatment advanced HCV with LADR. Hepatology 2005; 42: 255–62.
  • 148
    Johnson RJ, Willson R, Yamabe H et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994; 46: 125563.
  • 149
    Sabry AA, Sobh MA, Irving WL et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol. Dial. Transplant. 2002; 17: 23945.
  • 150
    Johnson RJ, Gretch DR, Yamabe H et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N. Engl. J. Med. 1993; 328: 46570.
  • 151
    Yamabe H, Johnson RJ, Gretch DR et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J. Am. Soc. Nephrol. 1995; 6: 2203.
  • 152
    Misiani R, Bellavita P, Fenili D et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann. Intern. Med. 1992; 117: 5735.
  • 153
    Bruchfeld A, Lindahl K, Stahle L et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol. Dial. Transplant. 2003; 18: 157380.
  • 154
    Teta D, Luscher BL, Gonvers JJ et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol. Dial. Transplant. 2005; 20: 9913.
  • 155
    Donahue JG, Munoz A, Ness PM et al. The declining risk of post-transfusion hepatitis C virus infection. N. Engl. J. Med. 1992; 327: 36973.
  • 156
    Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis patients and renal transplantation. Kidney Int. 1997; 51: 98199.
  • 157
    Dos Santos JP, Loureiro A, Cendoroglo Neto M et al. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol. Dial. Transplant. 1996; 11: 201722.
  • 158
    Froio N, Nicastri E, Comandini UV et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am. J. Kidney Dis. 2003; 42: 54650.
  • 159
    Glue P. The clinical pharmacology of ribavirin. Semin. Liver Dis. 1999; 19 (Suppl. 1): 1724.
  • 160
    Meyers CM, Seef LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis and renal disease: an update. Am. J. Kidney Dis. 2003; 42: 63157.
  • 161
    Fabrizi F, Dulai G, Dixit V et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment. Pharmacol. Ther. 2003; 18: 107181.
  • 162
    Russo MW, Golsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am. J. Gastroenterol. 2003; 98: 161015.
    Direct Link:
  • 163
    Campistol JM, Esforzado N, Martinez J et al. Efficacy and tolerance of interferon-alpha2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol. Dial. Transplant. 1999; 14: 27049.
  • 164
    Huraib S, Tanimu D, Romeh SA et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am. J. Kidney Dis. 1999; 34: 5560.
  • 165
    Pereira BJ, Wright TL, Schmid CH, Levey AS, for the New England Organ Bank Hepatitis C Study Group. The impact of pre-transplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799805.
  • 166
    Toth CM, Pascual M, Chung RT et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1998; 66: 12548.
  • 167
    Fabrizi F, Martin P, Dixit V et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transplant. 2005; 5: 145261.
  • 168
    Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin. Gastroenterol. Hepatol. 2005; 3: S11317.
  • 169
    Garnier JL, Chevallier P, Dubernard JM et al. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant. Proc. 1997; 29: 783.
  • 170
    Kamar N, Sandres-Saune K, Selves J, Ribes D. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am. J. Kidney Dis. 2003; 42: 18492.
  • 171
    Angastiniotis M, Modell B. Global epidemiology of haemoglobin disorders. Ann. N. Y. Acad. Sci. 1998; 850: 25169.
  • 172
    Wanachiwanawin W, Luengrojanakul P, Sirangkapracha P, Leowattana W, Fucharoen S. Prevalence and clinical significance of hepatitis C virus infection in Thai patients with thalassemia. Int. J. Hematol. 2003; 78: 3748.
  • 173
    Ansar MM, Koolobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J. Viral Hepat. 2002; 9: 3902.
  • 174
    Vento S, Cainelli F, Cesario F. Infections and thalassemia. Lancet Infect. Dis. 2006; 6: 22633.
  • 175
    Angelucci E, Muretto P, Nicolucci A et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 1: 1721.
  • 176
    Ryder SD. BSG, guidelines for the diagnosis and treatment of HCC in adults. Gut 2003; 52 (Suppl. 3): 18.
  • 177
    EASL International Consensus Conference on Hepatitis C. Paris, 26–27 February 1999. Consensus statement. J. Hepatol. 1999; 31 (Suppl. 1): 38.
  • 178
    Inati A, Taher A, Ghorra S et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassemia major patients with chronic hepatitis C virus infection. Br. J. Hematol. 2005; 130: 6446.
  • 179
    Pianko S, McHutchison JG, Gordon SC et al. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J. Interferon Cytokine Res. 2002; 22: 4839.
  • 180
    Tomas JF, Pinilla I, Garcia-Buey ML et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant. 2000; 26: 64955.
  • 181
    Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of haemophilia patients. Blood 1990; 1: 2546.
  • 182
    Preston FE, Jarvis LM, Makris M et al. Heterogeneity of hepatitis C virus genotypes in haemophilia, relationship with chronic liver disease. Blood 1995; 85: 125962.
  • 183
    Plug I, Van Der Bom JG, Peters M et al. Mortality and causes of death in patients with haemophilia, 1992–2001: a prospective cohort study. J. Thromb. Haemost. 2006; 4: 51016.
  • 184
    Zhang M, Rosenberg PS, Brown DL et al. Correlates of spontaneous clearance of hepatitis C virus among people with haemophilia. Blood 2006; 107: 8927.
  • 185
    National Institutes of Health. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens. State Sci. Statements 2002; 19: 146.
  • 186
    Theodore D, Fried MW, Kleiner DE et al. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia 2004; 10: 41321.
  • 187
    Stieltjes N, Ounnoughene N, Sava E et al. Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus. Br. J. Haematol. 2004; 125: 76976.
  • 188
    Maor Y, Bashari D, Kenet G et al. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 2006; 12: 3729.
  • 189
    Rumi MG, Santagostino E, Morfini M et al. A multicentre controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative haemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Haemophilia Centers. Blood 1997; 89: 352933.
  • 190
    Pinilla J, Quintana M, Magallon M. High-dose and long-term therapy of alpha interferon in haemophiliac patients with chronic C virus hepatitis. Blood 1998; 91: 7278.
  • 191
    Fried MW, Peter J, Hoots K et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002; 36: 96772.
  • 192
    Yamamoto K, Honda T, Matsushita T, Kojima T, Takamatsu J. Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with haemophilia: a possible mechanism of decreased events of bleeding in patients with haemophilia by ribavirin. J. Thromb. Haemost. 2006; 4: 46970.
  • 193
    Makris M, Baglin T, Dusheiko G et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001; 7: 33945.
  • 194
    Tanaka E, Kiyosawa K, Sodeyama T et al. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. Am. J. Trop Med. Hyg. 1992; 46: 4604.
  • 195
    Jafri W, Jafri N, Yakoob J et al. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect. Dis. 2006; 23: 101.
  • 196
    Lin JB, Lin DB, Chen SC, Chen PS, Chen WK. Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan. J. Med. Virol. 2006; 78: 1823.
  • 197
    Mast EE, Hwang LY, Seto DS et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J. Infect. Dis. 2005; 192: 18809.
  • 198
    European Pediatric Hepatitis C Network. A significant sex – but not elective cesarean section – effect on mother-to-child transmission of hepatitis C infection. J. Infect. Dis. 2005; 192: 18729.
  • 199
    Resti M, Jara P, Hierro L et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J. Med. Virol. 2003; 70: 3737.
  • 200
    Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J. Gastroenterol. Hepatol. 2004; 19: 135762.
  • 201
    Zuccotti GV, Salvini F, Farina F, Agostoni C, Riva E, Giovannini M. Longitudinal long-term follow-up study of children with vertically acquired hepatitis C virus infection. J. Int. Med. Res. 2006; 34: 21522.
  • 202
    Jara P, Resti M, Hierro L et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin. Infect. Dis. 2003; 36: 27580.
  • 203
    Birnbaum AH, Shneider BL, Moy L. Hepatitis C in children. N. Engl. J. Med. 2000; 342: 2901.
  • 204
    Barshes N. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl. 2006; 12: 10423.
  • 205
    Polywka S, Pembrey L, Tovo PA, Newell ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J. Med. Virol. 2006; 78: 30510.
  • 206
    Hardikar W, Elliott EJ, Jones CA. The silent infection: should we be testing for perinatal hepatitis C and, if so, how? Med. J. Aust. 2006; 184: 545.
  • 207
    Wirth S, Pieper-Boustani H, Lang T et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 101318.
  • 208
    Schwarz KB, Mohan P, Narkewicz MR et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 KD) in children with chronic hepatitis C. J. Pediatr. Gastroenterol. Nutr. 2006; 43: 499505.
  • 209
    Amin J, Kaye M, Skidmore S et al. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004; 5: 1749.
  • 210
    Dore GJ, Cooper DA. The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Curr. Opin. Infect. Dis.. 2001; 14: 74955.
  • 211
    Law WP, Dore GJ, Duncombe CJ et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001. AIDS 2003; 17:21919.
  • 212
    Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis. 2005; 192: 9921002.
  • 213
    Mocroft A, Soriano V, Rockstroh J et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 211725.
  • 214
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 2004; 351: 43850.
  • 215
    Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 283948.
  • 216
    Mauss S, Valenti W, DePamphilis J et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18: F215.
  • 217
    Atanasova MV, Haydouchka IA, Zlatev SP, Stoilova YD, Iliev YT, Mateva NG. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. Minerva Gastroenterol. Dietol. 2004; 50: 8996.
  • 218
    Shiratori Y, Shiina S, Zhang PY et al. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer 1997; 80: 20607.
  • 219
    Sato S, Fujiyama S, Tanaka M et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J. Hepatol. 1994; 21: 15966.
  • 220
    Ohkawa K, Hayashi N, Yuki N et al. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J. Hepatol. 1994; 21: 50914.
  • 221
    Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22: 11018.
  • 222
    Chan CY, Lee SD, Wu JC et al. Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B. Scand. J. Infect. Dis. 1991; 23: 4214.
  • 223
    Gaeta GB, Stornaiuolo G, Precone DF et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J. Hepatol. 2003; 39: 103641.
  • 224
    Di Marco V, Lo Iacono O, Camma C et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 25764.
  • 225
    Fattovich G, Tagger A, Brollo L et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J. Infect. Dis. 1991; 163: 4002.
  • 226
    Crespo J, Lozano JL, De La Cruz F et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am. J. Gastroenterol. 1994; 89: 114751.
  • 227
    Pallas JR, Farinas-Alvarez C, Prieto D, Delgado-Rodriguez M. Co-infections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur. J. Epidemiol. 1999; 15: 699704.
  • 228
    Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 10249.
  • 229
    Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J. Gastroenterol. 2002; 37 (Suppl. 13): 658.
  • 230
    Jardi R, Rodriguez F, Buti M et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34: 40410.
  • 231
    Liaw YF. Concurrent hepatitis B and C virus infection: is hepatitis C virus stronger? J. Gastroenterol. Hepatol. 2001; 16: 5978.
  • 232
    Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann. Clin. Microbiol. Antimicrob. 2005; 4: 1324.
  • 233
    Liaw YF, Chu CM, Chang-Chien CS, Wui CS. Simultaneous acute infections with hepatitis non-A, non-B, and B viruses. Dig. Dis. Sci. 1982; 27: 7624.
  • 234
    Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology 1994; 107: 18995.
  • 235
    Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am. J. Gastroenterol. 2000; 95: 297880.
    Direct Link:
  • 236
    Wu JC, Chen CL, Hou MC, Chen TZ, Lee SD, Lo KJ. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B. application and limitations of the polymerase chain reaction. Hepatology 1994; 19: 83640.
  • 237
    Fong TL, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991; 14: 647.
  • 238
    Mohamed Ael S, Al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997; 44: 14046.
  • 239
    Benvegnu L, Fattovich G, Noventa F et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 24428.
  • 240
    Chiaramonte M, Stroffolini T, Vian A et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 21327.
  • 241
    Weltman MD, Brotodihardjo A, Crewe EB et al. Coinfection with hepatitis B and C, or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J. Viral Hepat. 1995; 2: 3945.
  • 242
    Kaklamani E, Trichopoulos D, Tzonou A et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991; 265: 19746.
  • 243
    Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997; 112: 1847.
  • 244
    Guptan RC, Thakur V, Raina V, Sarin SK. Alfa-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J. Gastroenterol. Hepatol. 1999; 14: 8938.
  • 245
    Villa E, Grottola A, Buttafoco P et al. High doses of alfa-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am. J. Gastroenterol. 2001; 96: 29737.
  • 246
    Liaw YF, Chien RN, Lin SM et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J. Interferon Cytokine Res. 1997; 17: 44952.
  • 247
    Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37: 56876.
  • 248
    Hung CH, Lee CM, Lu SN et al. Combination therapy with interferon-alfa and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J. Gastroenterol. Hepatol. 2005; 20: 72732.
  • 249
    Chuang WL, Dai CY, Chang WY et al. Viral interaction and responses in chronic hepatitis C and B co-infected patients with interferon-alfa plus ribavirin combination therapy. Antivir. Ther. 2005; 10: 12533.
  • 250
    Marrone A, Zampino R, D'Onofrio M, Ricciotti R, Ruggiero G, Utili R. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J. Hepatol. 2004; 41: 10645.
  • 251
    Lunel F, Musset L, Cacoub P et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106: 1291300.
  • 252
    Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 2002; 36: 97885.
  • 253
    Rossi P, Bertani T, Baio P et al. Hepatitis C virus related cryoglobulinemic glomerulonephritis. Long-term remission after antiviral therapy. Kidney Int. 2003; 63: 223641.
  • 254
    Alric L, Plaisier E, Thebault S et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am. J. Kidney Dis. 2004; 43: 61723.
  • 255
    Johnson RJ, Grecht DR, Yamabe H et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. New Engl. J. Med. 1993; 328: 46570.
  • 256
    Yamabe H, Johnson RJ, Gretch DR et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J. Am. Soc. Nephrol. 1995; 6: 2203.
  • 257
    D'Amico G, Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am. J. Kidney Dis. 1995; 25: 3619.
  • 258
    Alric L, Plaisier E, Thebaulr S et al. Influence of antiviral therapy in hepatitis C virus associated cryoglobulinemia MPGN. Am. J. Kidney Dis. 2004; 43: 61723.
  • 259
    Philipnert M, Bastani B. Kidney diseases in patients with chronic hepatitis C. Curr. Gastroenterol. Rep. 2001; 3: 7983.
  • 260
    Cacoub P, Saedoun D, Limal N, Leger JM, Maisonobe T. Hepatitis C virus infection and mixed cryoglobulinemia vasculitis: a review of neurological complication. AIDS 2005; 19: S12834.
  • 261
    De Marino L, Sampaolo S, Tucci C et al. Viral RNA in nerve tissues of patients with hepatitis C infection and peripheral neuropathy. Muscle Nerve 2003; 27: 1024.
  • 262
    Ramos-Casals M, Trejo O, Garcia-Carrasco M, Font J. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford). 2003; 42: 81828.
  • 263
    Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphomas a meta-analysis of epidemiological studies. Cancer Sci. 2004; 95: 74552.
  • 264
    Gisberg JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment. Pharmacol. Ther. 2005; 21: 65362.
  • 265
    Takeshita M, Sakai H, Okamura S et al. Prevalence of hepatitis C virus infection cases of B-cell lymphoma in Japan. Histopathology 2006; 48: 18998.
  • 266
    Zuckerman E, Zuckerman T, Levine A et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann. Intern. Med. 1997; 127: 4238.
  • 267
    Silvestri F, Pipan C, Barillari G et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996; 87: 4296301.
  • 268
    Ferri C, Sebastiani M, Giuggioli D et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin. Arthritis Rheum. 2004; 33: 35574.
  • 269
    Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. Pegylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2005; 52: 91115.
  • 270
    Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J. Hepatol. 2003; 39: 6207.
  • 271
    Bonkovsky HL, Poh-Fitzpatrick M, Pimatone N et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 16619.
  • 272
    Poynard T, Cacoub P, Ratziu V et al. Fatigue in patients with chronic hepatitis C. J. Viral Hepat. 2002; 9: 295303.
  • 273
    Zuckerman E, Keren D, Rozenbaum M et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin. Exp. Rheumatol. 2000; 18: 57984.
  • 274
    Lee DH, Jamal H, Regnestein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in tertiary cure medical centre. Dig. Dis. Sci. 1997; 42: 18691.
  • 275
    Goh J, Coughlan B, Quinn J, O'Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorder in chronic hepatitis C infection. J. Gastroenterol. Hepatol. 1999; 11: 8338.
  • 276
    Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am. J. Gastroenterol. 1999; 94: 135560.
  • 277
    Cacoub P, Ratziu V, Myers RP et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J. Hepatol. 2002; 36: 81218.